Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1. At 48 weeks, BIC + LEN (at either LEN dose) was highly effective at maintaining virologic suppression and was well tolerated.
Authors
- Karam Mounzer (ORCID: https://orcid.org/0000-0001-8537-7103)
- Peter Sklar (ORCID: https://orcid.org/0009-0000-7071-6942)
- Malcolm Hedgcock (ORCID: https://orcid.org/0000-0001-7510-2173)
- Sorana Segal‐Maurer
- Jorge Santana‐Bagur (ORCID: https://orcid.org/0000-0003-2822-3401)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- Jairo Mauricio Montezuma-Rusca (ORCID: https://orcid.org/0000-0002-8391-1242)
- Xu Zhang (ORCID: https://orcid.org/0009-0004-0382-837X)
- Mark Bloch
- Keith Aizen (ORCID: https://orcid.org/0009-0009-2763-8745)
Institutions
- Spectrum Health (US)
- Midway University (US)
- New York Medical College (US)
- University of Puerto Rico System (PR)
- Corewell Health Blodgett Hospital (US)
- Gilead Sciences (United States) (US)
- Philadelphia Fight (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/ofid/ofaf615
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Gilead Sciences
- ViiV Healthcare